{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T04:43:58Z","timestamp":1792817038663,"version":"4.5.0"},"reference-count":32,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,9,3]],"date-time":"2021-09-03T00:00:00Z","timestamp":1630627200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,9,3]],"date-time":"2021-09-03T00:00:00Z","timestamp":1630627200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Med Genomics"],"published-print":{"date-parts":[[2021,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Background<\/jats:title><jats:p>Adenosquamous carcinoma of the prostate (ASCP) is an extremely rare and aggressive prostate cancer variant, whose genomic characteristics have not been elucidated. Although liquid biopsy of circulating tumor cells (CTCs) is an emerging topic in oncology, no study has assessed CTCs in patients with ASCP.<\/jats:p><jats:p>Case presentation.<\/jats:p><jats:p>A 76-year-old man presented with discomfort in his urethra. His prostate-specific antigen (PSA) level was 13.37\u00a0ng\/mL. A computed tomography (CT) scan indicated a prostate mass with multiple lymph node and lung metastases. The patient underwent transurethral resection of the prostate and prostatic needle biopsy; both specimens demonstrated Gleason grade group 5 acinar adenocarcinoma of the prostate. Bone scintigraphy indicated bone metastasis in the ischium. Combined androgen blockade was implemented, and his serum PSA level rapidly decreased to 0.01\u00a0ng\/mL. However, a CT scan 6\u00a0months after the initial diagnosis revealed worsening of the disease. The patient therefore underwent repeated prostatic needle biopsy; its specimen demonstrated prostatic adenocarcinoma together with squamous carcinoma components. As immunohistochemical analyses showed the tumor cells to be negative for CD56, chromogranin A, synaptophysin, and PSA, the definitive diagnosis was ASCP. Although the patient underwent chemotherapy (docetaxel and cabazitaxel), he died of the disease 3\u00a0months after the diagnosis of ASCP, or 13\u00a0months after the initial diagnosis of prostatic adenocarcinoma. His PSA values remained \u2264\u20090.2\u00a0ng\/mL. CTCs from the patient\u2019s blood (collected before starting docetaxel) were analyzed and genomically assessed. It showed 5 cytokeratin (CK)<jats:sup>+<\/jats:sup>CTCs, 14 CK<jats:sup>\u2212<\/jats:sup>CTCs, and 8 CTC clusters, per 10\u00a0mL. Next-generation sequencing identified a total of 14 mutations in 8 oncogenes or tumor suppressor genes:<jats:italic>PIK3CB<\/jats:italic>,<jats:italic>APC<\/jats:italic>,<jats:italic>CDKN2A<\/jats:italic>,<jats:italic>PTEN<\/jats:italic>,<jats:italic>BRCA2<\/jats:italic>,<jats:italic>RB1<\/jats:italic>,<jats:italic>TP53<\/jats:italic>, and<jats:italic>CDK12<\/jats:italic>. Of 14 mutations, 9 (64%) were detected on CK<jats:sup>\u2212<\/jats:sup>CTCs and 5 (36%) were detected on CK<jats:sup>+<\/jats:sup>CTCs.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>This is the first report of CTC analysis and genomic assessment in ASCP. Although the prognosis of ASCP is dismal due to lack of effective treatment, genomic analysis of CTCs might lead to effective treatment options and improved survival.<\/jats:p><\/jats:sec>","DOI":"10.1186\/s12920-021-01068-w","type":"journal-article","created":{"date-parts":[[2021,9,3]],"date-time":"2021-09-03T19:02:45Z","timestamp":1630695765000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":11,"title":["Genomic analysis of circulating tumor cells in adenosquamous carcinoma of the prostate: a case report"],"prefix":"10.1186","volume":"14","author":[{"given":"Junji","family":"Kitamura","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1291-4294","authenticated-orcid":false,"given":"Satoru","family":"Taguchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takatsugu","family":"Okegawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazuki","family":"Honda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toshihiko","family":"Kii","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshihiro","family":"Tomida","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryuki","family":"Matsumoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naoki","family":"Ninomiya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazuki","family":"Masuda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu","family":"Nakamura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tsuyoshi","family":"Yamaguchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manami","family":"Kinjo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mitsuhiro","family":"Tambo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aya","family":"Isomura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akimasa","family":"Hayashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroshi","family":"Kamma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eiji","family":"Higashihara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junji","family":"Shibahara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroshi","family":"Fukuhara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,9,3]]},"reference":[{"key":"1068_CR1","doi-asserted-by":"publisher","first-page":"260","DOI":"10.1097\/JU.0000000000001011","volume":"204","author":"C Bronkema","year":"2020","unstructured":"Bronkema C, Arora S, Sood A, et al. Rare histological variants of prostate adenocarcinoma: a national cancer database analysis. J Urol. 2020;204:260\u20136.","journal-title":"J Urol"},{"key":"1068_CR2","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1038\/pcan.2012.4","volume":"15","author":"DM Marcus","year":"2012","unstructured":"Marcus DM, Goodman M, Jani AB, Osunkoya AO, Rossi PJ. A comprehensive review of incidence and survival in patients with rare histological variants of prostate cancer in the United States from 1973 to 2008. Prostate Cancer Prostatic Dis. 2012;15:283\u20138.","journal-title":"Prostate Cancer Prostatic Dis"},{"key":"1068_CR3","doi-asserted-by":"publisher","first-page":"1105","DOI":"10.1001\/jama.1942.02830490025006","volume":"120","author":"GJ Thompson","year":"1942","unstructured":"Thompson GJ. Transurethral resection of malignant lesions of the prostate gland. JAMA. 1942;120:1105\u20139.","journal-title":"JAMA"},{"key":"1068_CR4","doi-asserted-by":"publisher","first-page":"651","DOI":"10.1097\/00000478-200405000-00014","volume":"28","author":"AV Parwani","year":"2004","unstructured":"Parwani AV, Kronz JD, Genega EM, Gaudin P, Chang S, Epstein JI. Prostate carcinoma with squamous differentiation: an analysis of 33 cases. Am J Surg Pathol. 2004;28:651\u20137.","journal-title":"Am J Surg Pathol"},{"key":"1068_CR5","doi-asserted-by":"publisher","first-page":"e47","DOI":"10.4081\/rt.2010.e47","volume":"2","author":"J Wang","year":"2010","unstructured":"Wang J, Wang FW, Lagrange CA, Hemstreet GP. Clinical features and outcomes of 25 patients with primary adenosquamous cell carcinoma of the prostate. Rare Tumors. 2010;2:e47.","journal-title":"Rare Tumors."},{"key":"1068_CR6","doi-asserted-by":"publisher","first-page":"561","DOI":"10.1016\/S0022-5347(17)60281-7","volume":"110","author":"RS Bennett","year":"1973","unstructured":"Bennett RS, Edgerton EO. Mixed prostatic carcinoma. J Urol. 1973;110:561\u20133.","journal-title":"J Urol"},{"key":"1068_CR7","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1016\/0090-4295(83)90355-2","volume":"22","author":"PA Accetta","year":"1983","unstructured":"Accetta PA, Gardner WA Jr. Adenosquamous carcinoma of prostate. Urology. 1983;22:73\u20135.","journal-title":"Urology"},{"key":"1068_CR8","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1016\/S0046-8177(84)80336-6","volume":"15","author":"R Saito","year":"1984","unstructured":"Saito R, Davis BK, Ollapally EP. Adenosquamous carcinoma of the prostate. Hum Pathol. 1984;15:87\u20139.","journal-title":"Hum Pathol"},{"key":"1068_CR9","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1097\/00000478-198705000-00010","volume":"11","author":"TN Moyana","year":"1987","unstructured":"Moyana TN. Adenosquamous carcinoma of the prostate. Am J Surg Pathol. 1987;11:403\u20137.","journal-title":"Am J Surg Pathol"},{"key":"1068_CR10","doi-asserted-by":"publisher","first-page":"1046","DOI":"10.1016\/0046-8177(91)90014-G","volume":"22","author":"DM Devaney","year":"1991","unstructured":"Devaney DM, Dorman A, Leader M. Adenosquamous carcinoma of the prostate: a case report. Hum Pathol. 1991;22:1046\u201350.","journal-title":"Hum Pathol"},{"key":"1068_CR11","doi-asserted-by":"publisher","first-page":"425","DOI":"10.3109\/00365599409180526","volume":"28","author":"M Ishigooka","year":"1994","unstructured":"Ishigooka M, Yaguchi H, Tomaru M, Sasagawa I, Nakada T, Mitobe K. Mixed prostatic carcinoma containing malignant squamous element. Reports of two cases. Scand J Urol Nephrol. 1994;28:425\u20137.","journal-title":"Scand J Urol Nephrol"},{"key":"1068_CR12","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1016\/0046-8177(95)90125-6","volume":"26","author":"P Gattuso","year":"1995","unstructured":"Gattuso P, Carson HJ, Candel A, Castelli MJ. Adenosquamous carcinoma of the prostate. Hum Pathol. 1995;26:123\u20136.","journal-title":"Hum Pathol"},{"key":"1068_CR13","doi-asserted-by":"publisher","first-page":"646","DOI":"10.1046\/j.1464-410X.1996.20830.x","volume":"78","author":"D Orhan","year":"1996","unstructured":"Orhan D, Sak SD, Yaman O, Tulunay O, G\u00f6g\u016d\u015f O. Adenosquamous carcinoma of the prostate. Br J Urol. 1996;78:646\u20137.","journal-title":"Br J Urol"},{"key":"1068_CR14","doi-asserted-by":"publisher","first-page":"832","DOI":"10.1016\/S0090-4295(98)00418-X","volume":"53","author":"TJ Bassler Jr","year":"1999","unstructured":"Bassler TJ Jr, Orozco R, Bassler IC, Boyle LM, Bormes T. Adenosquamous carcinoma of the prostate: case report with DNA analysis, immunohistochemistry, and literature review. Urology. 1999;53:832\u20134.","journal-title":"Urology"},{"key":"1068_CR15","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1023\/A:1007180024991","volume":"31","author":"OI Turhan","year":"1999","unstructured":"Turhan OI, Aydin NE, Sariy\u00fcce O. Adenosquamous carcinoma of the prostate. Int Urol Nephrol. 1999;31:89\u201393.","journal-title":"Int Urol Nephrol"},{"key":"1068_CR16","doi-asserted-by":"publisher","first-page":"396","DOI":"10.3349\/ymj.1999.40.4.396","volume":"40","author":"YW Kim","year":"1999","unstructured":"Kim YW, Park YK, Park JH, et al. Adenosquamous carcinoma of the prostate. Yonsei Med J. 1999;40:396\u20139.","journal-title":"Yonsei Med J"},{"key":"1068_CR17","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1038\/sj.pcan.4500388","volume":"3","author":"M Helal","year":"2000","unstructured":"Helal M, Diaz JI, Tannenbaum A, Greenberg H, Lockhart J. Postradiation therapy adenosquamous cell carcinoma of the prostate. Prostate Cancer Prostatic Dis. 2000;3:53\u20136.","journal-title":"Prostate Cancer Prostatic Dis"},{"key":"1068_CR18","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1111\/j.1442-2042.2005.01036.x","volume":"12","author":"T Egilmez","year":"2005","unstructured":"Egilmez T, Bal N, Guvel S, Kilinc F, Ozkardes H. Adenosquamous carcinoma of the prostate. Int J Urol. 2005;12:319\u201321.","journal-title":"Int J Urol"},{"key":"1068_CR19","doi-asserted-by":"publisher","first-page":"2491","DOI":"10.1100\/tsw.2006.388","volume":"6","author":"DE Baydar","year":"2006","unstructured":"Baydar DE, Kosemehmetoglu K, Akdogan B, Ozen H. Prostatic adenosquamous carcinoma metastasizing to testis. ScientificWorldJournal. 2006;6:2491\u20134.","journal-title":"ScientificWorldJournal"},{"key":"1068_CR20","doi-asserted-by":"crossref","first-page":"1998","DOI":"10.3760\/cma.j.issn.0366-6999.20121500","volume":"126","author":"X Gao","year":"2013","unstructured":"Gao X, Wang HF, Li Y, et al. Treatment of bladder invasive adenosquamous carcinoma of the prostate: radical cystoprostatectomy. Chin Med J (Engl). 2013;126:1998.","journal-title":"Chin Med J (Engl)"},{"key":"1068_CR21","doi-asserted-by":"publisher","first-page":"e29","DOI":"10.1016\/j.clgc.2013.08.006","volume":"12","author":"S Mishra","year":"2014","unstructured":"Mishra S, Goel H, Awasthi N, Puri A, Mahapatra R, Pal DK. Primary adenosquamous carcinoma of the prostate: a rare aggressive tumor. Clin Genitourin Cancer. 2014;12:e29-31.","journal-title":"Clin Genitourin Cancer"},{"key":"1068_CR22","doi-asserted-by":"publisher","first-page":"2325","DOI":"10.3892\/ol.2014.2493","volume":"8","author":"Z Zhang","year":"2014","unstructured":"Zhang Z, Wang Y, Zhao Q, et al. Mixed adenocarcinoma, sarcomatoid carcinoma and adenosquamous carcinoma of the prostate: a case report. Oncol Lett. 2014;8:2325\u20137.","journal-title":"Oncol Lett"},{"key":"1068_CR23","doi-asserted-by":"publisher","first-page":"e71","DOI":"10.1097\/PAI.0000000000000443","volume":"25","author":"AM Acosta","year":"2017","unstructured":"Acosta AM, Kajdacsy-Balla A, Groth JV. The squamous cells of adenosquamous carcinoma (ASCC) of the prostate might represent a terminally differentiated quiescent component: immunohistochemical evidence from a case of ASCC with pleomorphic giant tumor cells. Appl Immunohistochem Mol Morphol. 2017;25:e71\u20133.","journal-title":"Appl Immunohistochem Mol Morphol"},{"key":"1068_CR24","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1016\/j.ejca.2018.01.086","volume":"95","author":"C Eze","year":"2018","unstructured":"Eze C, Manapov F, Gratzke C, et al. Concurrent radiotherapy and nivolumab in metachronous metastatic primary adenosquamous-cell carcinoma of the prostate. Eur J Cancer. 2018;95:109\u201311.","journal-title":"Eur J Cancer"},{"key":"1068_CR25","doi-asserted-by":"publisher","first-page":"101084","DOI":"10.1016\/j.eucr.2019.101084","volume":"29","author":"A Hennessey","year":"2019","unstructured":"Hennessey A, Buller D, Sama S, Girard E, Clement J, Ristau BT. Case report: adenosquamous carcinoma of the prostate with greater than 20 month response to multimodal therapy. Urol Case Rep. 2019;29:101084.","journal-title":"Urol Case Rep."},{"key":"1068_CR26","doi-asserted-by":"publisher","first-page":"890","DOI":"10.1111\/his.14205","volume":"77","author":"M Alhamar","year":"2020","unstructured":"Alhamar M, Tudor Vladislav I, Smith SC, et al. Gene fusion characterisation of rare aggressive prostate cancer variants-adenosquamous carcinoma, pleomorphic giant-cell carcinoma, and sarcomatoid carcinoma: an analysis of 19 cases. Histopathology. 2020;77:890\u20139.","journal-title":"Histopathology"},{"key":"1068_CR27","doi-asserted-by":"publisher","first-page":"6302","DOI":"10.1158\/1078-0432.CCR-08-0872","volume":"14","author":"JS de Bono","year":"2008","unstructured":"de Bono JS, Scher HI, Montgomery RB, et al. Circulating tumor cells predict survival benefit from treatment in metastatic castration-resistant prostate cancer. Clin Cancer Res. 2008;14:6302\u20139.","journal-title":"Clin Cancer Res"},{"key":"1068_CR28","doi-asserted-by":"publisher","first-page":"1028","DOI":"10.1056\/NEJMoa1315815","volume":"371","author":"ES Antonarakis","year":"2014","unstructured":"Antonarakis ES, Lu C, Wang H, et al. AR-V7 and resistance to enzalutamide and abiraterone in prostate cancer. N Engl J Med. 2014;371:1028\u201338.","journal-title":"N Engl J Med"},{"key":"1068_CR29","doi-asserted-by":"publisher","first-page":"576","DOI":"10.1002\/pros.23501","volume":"78","author":"T Okegawa","year":"2018","unstructured":"Okegawa T, Ninomiya N, Masuda K, Nakamura Y, Tambo M, Nutahara K. AR-V7 in circulating tumor cells cluster as a predictive biomarker of abiraterone acetate and enzalutamide treatment in castration-resistant prostate cancer patients. Prostate. 2018;78:576\u201382.","journal-title":"Prostate"},{"key":"1068_CR30","doi-asserted-by":"publisher","first-page":"e0130418","DOI":"10.1371\/journal.pone.0130418","volume":"10","author":"A Morimoto","year":"2015","unstructured":"Morimoto A, Mogami T, Watanabe M, et al. High-density dielectrophoretic microwell array for detection, capture, and single-cell analysis of rare tumor cells in peripheral blood. PLoS ONE. 2015;10:e0130418.","journal-title":"PLoS ONE"},{"key":"1068_CR31","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1038\/sj.bjc.6690669","volume":"81","author":"S Wang-Gohrke","year":"1999","unstructured":"Wang-Gohrke S, Weikel W, Risch H, et al. Intron variants of the p53 gene are associated with increased risk for ovarian cancer but not in carriers of BRCA1 or BRCA2 germline mutations. Br J Cancer. 1999;81:179\u201383.","journal-title":"Br J Cancer"},{"key":"1068_CR32","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1038\/s41389-019-0141-3","volume":"8","author":"J Smeby","year":"2019","unstructured":"Smeby J, Sveen A, Eilertsen IA, et al. Transcriptional and functional consequences of TP53 splice mutations in colorectal cancer. Oncogenesis. 2019;8:35.","journal-title":"Oncogenesis"}],"container-title":["BMC Medical Genomics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12920-021-01068-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12920-021-01068-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12920-021-01068-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,9,7]],"date-time":"2024-09-07T19:10:55Z","timestamp":1725736255000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcmedgenomics.biomedcentral.com\/articles\/10.1186\/s12920-021-01068-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,9,3]]},"references-count":32,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,12]]}},"alternative-id":["1068"],"URL":"https:\/\/doi.org\/10.1186\/s12920-021-01068-w","relation":{},"ISSN":["1755-8794"],"issn-type":[{"value":"1755-8794","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,9,3]]},"assertion":[{"value":"2 March 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 August 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 September 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study has been approved by the Institutional Review Board of Life Science Research Laboratory, Tosoh Corporation (Protocols LS18-02 and LS19-02) and Kyorin University School of Medicine (approval number 1205). Written informed consent to participate in this study was obtained from the patient.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Written informed consent was obtained from the patient for publication in the appropriate journal.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"217"}}